Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study

NCT07828314 | Completed DMC

• 1 other identifier: PHU/2025/27
• Study Type: observational
• Target: 118
• Locations: 1 country
• Sites: 1

Brief Summary

Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the consent process

Conditions

Oesophageal Cancer

Outcome Measures

Primary Outcomes (1)

• Patient priorities

  Interview responses and responses from discrete choice experiment.

  6 months

Study Arms (2)

Stage 1

Semi-structured interviews

Behavioral: Semi-structured interview

Stage 2

Discrete choice experiment

Behavioral: Discrete Choice Experiment

Interventions

Semi-structured interview BEHAVIORAL

Interviews will be facilitated by the research team. The sessions will be designed to follow the consolidated criteria for reporting qualitative research (COREQ) (12). The Questionnaire on Distress in Cancer Patients and The Cancer Worry Scale (both validated patient surveys) were also used to help design the script for the interview. The full interview script can be found in a separate document entitled "Patient priorities in Oesophageal Cancer".

Stage 1

Discrete Choice Experiment BEHAVIORAL

Participants will be asked to imagine the following scenario; "You have undergone endoscopic resection for an early oesophageal cancer. All your cancer has been removed, but the histology from your endoscopic resection shows you are at an increased risk of recurrence. This risk could be reduced by undergoing a radical oesophagectomy. The following options are presented to you;" \- Questionnaire will involve choosing between 2 treatments options; Active surveillance or radical surgery. * 5 attributes will be assigned to each treatment option. Examples of possible attributes; 5-year survival (this pertains to risk of nodal/distant metastases) Risk of mortality from surgery Short-term HRQoL Long-term HRQoL Frequency of invasive tests * Each attribute will have 3 levels * It would not be possible to expose patients to all choice sets (\>200). Software will be used to design 20 choice sets that will make up the questionnaire.

Stage 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are undergoing surveillance or endoscopic treatment for Barret's oesophagus, dysplasia, or oesophageal cancer.

You may qualify if:

• Under care of local MDT for monitoring/surveillance/treatment of Barretts/dysplasia/oesophageal cancer
• able to communicate in English Language

You may not qualify if:

• Unable or unwilling to give informed consent

Sponsors & Collaborators

• Portsmouth Hospitals NHS Trust: lead

Study Sites (1)

Portsmouth Hospitals University NHS Trust

Portsmouth, Hampshire, PO6 3LY, United Kingdom

Location

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 14, 2026
• First Posted: September 18, 2026
• Study Start: August 6, 2025
• Primary Completion: August 1, 2026
• Study Completion: August 1, 2026
• Last Updated: September 18, 2026

Record last verified: 2026-09

Locations

GB (1)